Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

ADC Therapeutics begins dosing in ADCT-402 Phase I trial for B-NHL patients

Go Top